Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study.

Selma Tobudic Christina Forstner Lisa SchneiderEmilia PaulussenLucie Bartonickova Stefan HagelPeter StarzengruberHeinz BurgmannMathias W Pletz

Published in: Infection (2023)

Our study suggests that initial use of PIP/TAZ may be associated with reduced early treatment response in E. coli BSI caused by AMP/SLB-resistant isolates compared to alternative monotherapies.

Keyphrases

escherichia coli
klebsiella pneumoniae
protein kinase
biofilm formation
staphylococcus aureus
drug resistant